Surmodics (SRDX)
(Delayed Data from NSDQ)
$37.66 USD
+0.09 (0.24%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $37.66 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$37.66 USD
+0.09 (0.24%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $37.66 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
D Value B Growth B Momentum B VGM
Zacks News
PRA Health Unit to Offer Free Access to Metys COVID-19 Module
by Zacks Equity Research
PRA Health's (PRAH) new module is likely to boost Data Solutions segment.
Bio-Rad Rides on International Expansion Amid Cost Concerns
by Zacks Equity Research
Each of Bio-Rad's (BIO) key segments registers solid growth across three major geographies of America, Europe and Asia.
Hologic (HOLX) Posts Q2 Preliminary Results, Withdraws View
by Zacks Equity Research
Investors remain optimistic with Hologic's (HOLX) balanced segmental preliminary revenue results for second-quarter fiscal 2020.
Here's Why You Should Add Surmodics to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high in Surmodics' (SRDX) stock,thanks to solid prospects.
SurModics (SRDX) Down 22.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Surmodics (SRDX) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Surmodics' (SRDX) fiscal first-quarter earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.
SurModics (SRDX) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 266.67% and -0.89%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: SurModics (SRDX) Q1 Earnings Expected to Decline
by Zacks Equity Research
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: SurModics (SRDX) Q1 Earnings Expected to Decline
by Zacks Equity Research
SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Surmodics (SRDX) Stock for Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.
Here's Why You Should Hold on to Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.
Surmodics (SRDX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q4.
SurModics (SRDX) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 5.71% and 8.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
LabCorp (LH) Q3 Earnings Surpass Estimates, Tapers View
by Zacks Equity Research
LabCorp (LH) impresses investors with third-quarter 2019 results on the robust performance of the Covance Drug Development segment.
Here's Why You Should Hold on to Abbott (ABT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Abbott's (ABT) performance.
ResMed Upgrades Nasal Care by Introducing Cradle CPAP Mask
by Zacks Equity Research
ResMed (RMD) revolutionizes sleep apnea treatment by introducing a hassle-free and easy-to-use mask.
Medical Products Industry Outlook: Prospects Seem Promising
by Trina Mukherjee
Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.
Here's Why You Should Hold on to Chemed (CHE) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about Chemed's (CHE) performance.
Organigram (OGI) Catches Eye: Stock Jumps 8.6%
by Zacks Equity Research
Organigram (OGI) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Here's Why You Should Invest in Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.
Top Ranked Momentum Stocks to Buy for September 26th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 26th
Will SurModics (SRDX) Gain on Rising Earnings Estimates?
by Zacks Equity Research
SurModics (SRDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Bulls Roaring Despite Slowdown Fears: 5 Top Picks
by Nalak Das
Year to date, the performance on Wall Street is projecting a glorious picture with no end to the bull run in sight, at least this year.
Stryker's Mobius Imaging Buyout to Boost Its Spine Division
by Zacks Equity Research
Stryker (SYK) expects the buyout to remain neutral to its 2019 earnings.
Here's Why You Should Invest in Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.